Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms

FDA nod to first-ever treatment for fatal pediatric Menkes disease

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy

REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS

GSK’s Nucala approved in China for COPD with high eosinophils

Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL

MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial

Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit

Singapore clears AI bladder cancer detection tool

CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes

SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent

The study will run across 18 sites and enroll roughly 200 patients over 24 months

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026